CClinicalTrials.gg
CompletedNCT00392158Updated Sep 26, 2016

Manual Administration of Propofol-remifentanil Versus Dual Closed-loop Using Bispectral Index as the Control Variable

A Phase 4 interventional study of Closed-loop anesthesia system in Anesthesia, General, sponsored by Hopital Foch. Completed at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-26.

Sponsored by Hopital Foch · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To compare manual administration of propofol and remifentanil and dual closed-loop using bispectral index as the control variable during anesthesia

Read the detailed description

The Bispectral Index (BIS) is an electroencephalogram-derived measure of anesthetic depth. A closed-loop anesthesia system can be built using BIS as the control variable, a proportional-integral-differential control algorithm, and a propofol target-controlled infusion system as the control actuator. Recent studies have shown that such system is able to provide clinically adequate anesthesia. We hypothesized that BIS can also indicate the adequacy of analgesia and therefore built a combined closed-loop anesthesia system using BIS as the control variable, two proportional-integral-differential control algorithms, a propofol and a remifentanil target-controlled infusion systems as the control actuators. In preparation for a large multi-center control trial, we propose a prospective randomized study to evaluate the effectiveness of such a closed-loop anesthesia system. Two groups of patients are compared: one in which propofol and remifentanil are administered by the anesthesiologist using target-controlled infusion systems, and one in which propofol and remifentanil are administered automatically by the combined closed-loop anesthesia system. In both groups, the goal is to maintain BIS between 40 and 60, the recommended range during anesthesia by the manufacturer. We expect the combined closed-loop anesthesia system group to do similar or better.

02

Conditions studied

  • Anesthesia, General
03

In context

Lead sponsor

Hopital Foch is the lead sponsor of 208 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • surgery under general anesthesia using relaxant agent,
  • surgery lasting more than one hour

Exclusion criteria

Exclusion Criteria:

  • pregnant women,
  • indication for rapid sequence induction,
  • anticipation of difficult intubation,
  • allergy to propofol or remifentanil,
  • neurological or muscular disorder,
  • combination of general anesthesia and of regional anesthesia,
  • emergency surgery.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants

Interventions

  • DeviceClosed-loop anesthesia system
06

What researchers measure

Primary outcomes

  1. Global score (calculated parameter which depicts the performance of the system, i.e. its capacity to maintain BIS in the desired range)

Secondary outcomes

  1. consumption of propofol and remifentanil during the induction and the maintenance of the anaesthesia

  2. number of modifications of target of propofol and remifentanil

  3. number of episodes of hemodynamic anomalies having required a treatment

  4. intraoperative volume loading and transfusion

  5. extubation time, explicit memorisation

  6. dysfunctions of each system

07

Study locations

6 sites
  • Dept of Anesthesia, CH d'Argenteuil
    Argenteuil, 95100, France
  • Dept of Anesthesiology, CHU de Besançon
    Besançon, 25030, France
  • Dept of Anesthesia, Clinique Saint Augustin
    Bordeaux, 33074, France
  • Dept of Anesthesia and Intensive Care, Hôpital Beaujon
    Clichy, 92110, France
  • Dept of Anesthesiology, Hôpital Cochin
    Paris, 75014, France
  • Dept of Anesthesia, Hôpital Foch
    Suresnes, 92150, France
08

References and documents

Publications

  • Liu N, Chazot T, Genty A, Landais A, Restoux A, McGee K, Laloe PA, Trillat B, Barvais L, Fischler M. Titration of propofol for anesthetic induction and maintenance guided by the bispectral index: closed-loop versus manual control: a prospective, randomized, multicenter study. Anesthesiology. 2006 Apr;104(4):686-95. doi: 10.1097/00000542-200604000-00012. PubMed 16571963 ↗
  • Liu N, Chazot T, Trillat B, Pirracchio R, Law-Koune JD, Barvais L, Fischler M. Feasibility of closed-loop titration of propofol guided by the Bispectral Index for general anaesthesia induction: a prospective randomized study. Eur J Anaesthesiol. 2006 Jun;23(6):465-9. doi: 10.1017/S0265021506000196. PubMed 16672092 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00392158
Lead sponsor
Hopital Foch
First posted
Oct 25, 2006
Start date
Feb 2006
Completion
Apr 2007
Last update
Sep 26, 2016

Study contacts

Marc Fischler, MD
principal investigator · Hôpital Foch

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion